It started in the operating room.

Matthew Maale, MS

Co-founder · CEO

Trained in biomedical engineering (MS, UT Dallas), with medtech R&D, prototyping, validation and regulatory strategy experience. Built an ISO 13485-certified medical packaging and device company and led MicoCalo from concept to a bench prototype. Named inventor on MicoCalo’s patent application.

Completed the Alloy Futures Biotech Startup Academy and the UT Dallas CometX Accelerator in 2026, leads the Dallas–Fort Worth chapter of Bits in Bio, and is a mentor for Nucleate Executive Training (NEXT). Nucleate was named to TIME’s first list of America’s Best Incubators and Accelerators in 2026.

Gerhard E. Maale III, MD

Co-founder · Advisor

Orthopedic oncology and revision surgeon with decades of operative and infection-management experience. First author of a published series of 500 one-stage revisions for infected joint replacements, 351 of them knees (Biofilm, 2020), and of a one-stage technique for infected knee revisions with large anterior soft-tissue defects (Techniques in Orthopaedics, 2022).

Named inventor on ten granted US patents for orthopedic implants and bone-cement devices, and on MicoCalo’s pending patent application. Earlier worked on rapid molecular identification of bacteria in orthopedic infections with the Ibis platform.

Gregory J. Tobin, PhD

Co-founder · Advisor

Molecular biologist and immunologist with deep platform-development experience. PI or lead scientist on more than 25 NIH- and DoD-funded research projects, co-author of at least 40 peer-reviewed articles, and named on 12 patents and patent applications. Co-founded Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company. Named inventor on MicoCalo’s patent application.

Stephen J. Dollery, PhD

Co-founder · Advisor

Molecular virologist with NIH and industry experience spanning diagnostics, vaccines and translational infectious-disease research. Co-authored diagnostic and vaccine publications and helped develop multiple molecular detection platforms. Named inventor on MicoCalo’s patent application.

Taralyn Wiggins, MS

Co-founder · Advisor

Program manager and molecular biologist with vaccine and diagnostic development experience. At an earlier team venture, she led market research, headed its NSF I-Corps regional customer-discovery work and prepared investor and incubator pitch materials.